Dr Reddy’s launches injectable in US

News: Dr Reddy’s has launched Methylprednisolone Sodium Succinate for Injection (generic of SOLU-MEDROL) in US. The estimated market size for approved drug, brand and generic is ~ US$144 million (IQVIA Health, MAT February 2022). Dr. Reddy’s Methylprednisolone Sodium Succinate for Injection, is supplied in strengths of 40 mg/vial and 125 mg/vial single dose vial, 500 mg and 1 gm multi-dose vial

Views: This is a niche injectable launch with limited competition, in alignment with the strategy to offset price erosion in US generics. Ramp-up in sales and market share gains in such launches will be key monitorable. We expect Dr Reddy’s US business to grow at CAGR of 7.5% over FY21-24E to Rs 8750 crore

Impact: Positive